Episode 174 - February 27, 2026 | Biotech Hangout

The podcast centers on the FDA's evolving regulatory standards and their impact on biomedical innovation, particularly in rare diseases. The discussion highlights the perceived discordance between the FDA's stated goals of regulatory flexibility and its recent actions, citing examples like the CRL for Atara and Pierre Fabre's drug, where clinical deficiencies were raised after manufacturing issues were seemingly resolved. The panelists debate whether the new CBER leadership under Vinay Prasad is obligated to follow previous agreements and question the communication of changing standards to companies. Additional topics include Gilead's acquisition of Arcellx, Vir's encouraging data for its prostate cancer treatment, and Novo Nordisk's CagriSema failing to meet non-inferiority endpoints against Zepbound.

Outlines

Part 1: FDA Regulatory Landscape and Challenges

Part 2: Politics, Credibility, and Policy

Part 3: Clinical Trial Results and Market Impact

Part 4: Corporate Strategy and Leadership Transitions

Part 5: Future Outlook

Sign in to continue reading, translating and more.

Open full episode in Podwise

Episode 174 - February 27, 2026

Biotech Hangout

Part 1: FDA Regulatory Landscape and Challenges

FDA Updates: Regulatory Flexibility, Innovation, and Rare Disease Focus

Atara's Ebvallo Rejection: FDA Actions vs. Rhetoric on Rare Diseases

FDA Leadership Changes and Shifting Standards for Drug Approval

Decision-Making Processes at the FDA: Committee vs. Authoritarian Approaches

Part 2: Politics, Credibility, and Policy

Transparency, Stringency, and Political Pressures on the FDA

FDA Credibility: Politics, Philosophy, and Regulatory Decision-Making

Part 3: Clinical Trial Results and Market Impact

Gilead's Acquisition of Arcellx: An Unsurprising Move in Cell Therapy

Vir's T-Cell Engager Data and Astellas Partnership in Prostate Cancer

Novo Nordisk's CagriSema Fails Non-Inferiority Trial Against Zepbound

Gossamer's PAH Drug Fails Phase 3 Study

Palvella's Positive Phase 3 Data for Rare Skin Disorder

Part 4: Corporate Strategy and Leadership Transitions

Merck Reorganizes Business with Focus on Oncology Segment

Sarepta CEO Doug Ingram Steps Down

Alnylam's Richard Pops Retires After 35 Years

Part 5: Future Outlook

Xenon's Upcoming Data Readout for Focal Onset Seizures

Episode 174 - February 27, 2026

Biotech Hangout

Part 1: FDA Regulatory Landscape and Challenges

00:00FDA Updates: Regulatory Flexibility, Innovation, and Rare Disease Focus

FDA Updates: Regulatory Flexibility, Innovation, and Rare Disease Focus

02:37Atara's Ebvallo Rejection: FDA Actions vs. Rhetoric on Rare Diseases

Atara's Ebvallo Rejection: FDA Actions vs. Rhetoric on Rare Diseases

08:10FDA Leadership Changes and Shifting Standards for Drug Approval

FDA Leadership Changes and Shifting Standards for Drug Approval

12:13Decision-Making Processes at the FDA: Committee vs. Authoritarian Approaches

Decision-Making Processes at the FDA: Committee vs. Authoritarian Approaches

Part 2: Politics, Credibility, and Policy

15:24Transparency, Stringency, and Political Pressures on the FDA

Transparency, Stringency, and Political Pressures on the FDA

22:14FDA Credibility: Politics, Philosophy, and Regulatory Decision-Making

FDA Credibility: Politics, Philosophy, and Regulatory Decision-Making

Part 3: Clinical Trial Results and Market Impact

28:45Gilead's Acquisition of Arcellx: An Unsurprising Move in Cell Therapy

Gilead's Acquisition of Arcellx: An Unsurprising Move in Cell Therapy

31:23Vir's T-Cell Engager Data and Astellas Partnership in Prostate Cancer

Vir's T-Cell Engager Data and Astellas Partnership in Prostate Cancer

34:40Novo Nordisk's CagriSema Fails Non-Inferiority Trial Against Zepbound

Novo Nordisk's CagriSema Fails Non-Inferiority Trial Against Zepbound

40:06Gossamer's PAH Drug Fails Phase 3 Study

Gossamer's PAH Drug Fails Phase 3 Study

43:03Palvella's Positive Phase 3 Data for Rare Skin Disorder

Palvella's Positive Phase 3 Data for Rare Skin Disorder

Part 4: Corporate Strategy and Leadership Transitions

45:03Merck Reorganizes Business with Focus on Oncology Segment

Merck Reorganizes Business with Focus on Oncology Segment

46:08Sarepta CEO Doug Ingram Steps Down

Sarepta CEO Doug Ingram Steps Down

50:09Alnylam's Richard Pops Retires After 35 Years

Alnylam's Richard Pops Retires After 35 Years

Part 5: Future Outlook

52:04Xenon's Upcoming Data Readout for Focal Onset Seizures

Xenon's Upcoming Data Readout for Focal Onset Seizures